Analyst Information
Christopher RaymondSr. Research Analyst![]() Chris Raymond is a managing director and senior research analyst at Piper Sandler covering the biotechnology sector. Prior to joining Piper, he spent the previous 17 years covering biotechnology at Raymond James, Robert W. Baird and Prudential Vector Healthcare Group. Before that, he spent 10 years with Baxter Healthcare and G. D. Searle in various marketing, business development and strategy roles. Raymond has been recognized twice by StarMine as a top earnings estimator in biotechnology and in 2004 was recognized by The Wall Street Journal "Best on the Street" survey. Raymond received his bachelor’s degree from Michigan State University and his Master of Business Administration degree from the University of Chicago Graduate School of Business. He currently serves on the board of the Financial Markets Institute at Michigan State's Broad College of Business. |
Universe Coverage: Healthcare: Biotechnology | |
ABBV | AbbVie Inc. |
ACRS | Aclaris Therapeutics, Inc. |
AKBA | Akebia Therapeutics, Inc. |
ALXN | Alexion Pharmaceuticals, Inc. |
ALVR | AlloVir, Inc. |
ALXO | ALX Oncology Holdings, Inc. |
AMGN | Amgen Inc. |
APTX | Aptinyx Inc. |
ARDX | Ardelyx, Inc. |
ARGX | argenx SE |
BCRX | BioCryst Pharmaceuticals, Inc. |
BIIB | Biogen Inc. |
BMRN | BioMarin Pharmaceutical Inc. |
BPMC | Blueprint Medicines Corporation |
COGT | Cogent Biosciences, Inc. |
DCPH | Deciphera Pharmaceuticals, Inc. |
GRAY | Graybug Vision, Inc. |
INZY | Inozyme Pharma, Inc. |
ITOS | iTeos Therapeutics, Inc. |
KNTE | Kinnate Biopharma, Inc. |
MGTX | MeiraGTx Holdings Plc |
NUVL | Nuvalent, Inc. |
ONCR | Oncorus, Inc. |
OTIC | Otonomy, Inc. |
REGN | Regeneron Pharmaceuticals Inc. |
SLDB | Solid Biosciences Inc. |
RARE | Ultragenyx Pharmaceutical, Inc. |